Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation.

World Journal of Gastrointestinal Pathophysiology Pub Date : 2020-08-12 DOI:10.4291/wjgp.v11.i5.104

Simcha Weissman, Preetika Sinh, Tej I Mehta, Rishi K Thaker, Abraham Derman, Caleb Heiberger, Nabeel Qureshi, Viralkumar Amrutiya, Adam Atoot, Maneesh Dave, James H Tabibian

{"title":"Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation.","authors":"Simcha Weissman, Preetika Sinh, Tej I Mehta, Rishi K Thaker, Abraham Derman, Caleb Heiberger, Nabeel Qureshi, Viralkumar Amrutiya, Adam Atoot, Maneesh Dave, James H Tabibian","doi":"10.4291/wjgp.v11.i5.104","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) causes systemic vascular inflammation. The increased risk of venous as well as arterial thromboembolic phenomena in IBD is well established. More recently, a relationship between IBD and atherosclerotic cardiovascular disease (ASCVD) has been postulated. Systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have well characterized cardiac pathologies and treatments that focus on prevention of disease associated ASCVD. The impact of chronic inflammation on ASCVD in IBD remains poorly characterized. This manuscript aims to review and summarize the current literature pertaining to IBD and ASCVD with respect to its pathophysiology and impact of medications in order to encourage further research that can improve understanding and help develop clinical recommendations for prevention and management of ASCVD in patients with IBD.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"11 5","pages":"104-113"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/78/WJGP-11-104.PMC7403753.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Pathophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4291/wjgp.v11.i5.104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Inflammatory bowel disease (IBD) causes systemic vascular inflammation. The increased risk of venous as well as arterial thromboembolic phenomena in IBD is well established. More recently, a relationship between IBD and atherosclerotic cardiovascular disease (ASCVD) has been postulated. Systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have well characterized cardiac pathologies and treatments that focus on prevention of disease associated ASCVD. The impact of chronic inflammation on ASCVD in IBD remains poorly characterized. This manuscript aims to review and summarize the current literature pertaining to IBD and ASCVD with respect to its pathophysiology and impact of medications in order to encourage further research that can improve understanding and help develop clinical recommendations for prevention and management of ASCVD in patients with IBD.

Abstract Image

查看原文本刊更多论文

炎症性肠病中的动脉粥样硬化性心血管疾病：慢性炎症的作用

炎症性肠病（IBD）会引起全身血管炎症。IBD 患者发生静脉和动脉血栓栓塞现象的风险增加已得到公认。最近，有人推测 IBD 与动脉粥样硬化性心血管疾病（ASCVD）之间存在关系。类风湿性关节炎和系统性红斑狼疮等全身性炎症性疾病具有明显的心脏病理特征，其治疗重点是预防与疾病相关的 ASCVD。而慢性炎症对 IBD 患者 ASCVD 的影响尚不明确。本手稿旨在回顾和总结目前有关 IBD 和 ASCVD 的病理生理学和药物影响方面的文献，以鼓励进一步的研究，从而提高对 IBD 患者 ASCVD 预防和管理的认识并帮助制定临床建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Gastrointestinal Pathophysiology

自引率

0.00%

发文量